Industry News/Blood Substitutes

Patent Allowed for Selective Cross-Linking of Hemoglobin

Published in Blood Weekly, June 26th, 1995

Hemosol Inc., Toronto, Ontario, Canada, reported the allowance of U.S. Patent Application No. 08/231,945 for a reproducible and scaleable process for crosslinked and oligomerized hemoglobin suitable for use as a red blood cell substitute.

The principal application of this process is the selective and controlled cross-linking of purified human hemoglobin Ao by oxidized, ring-opened sugars. The technology applies to the production of Hemolink, Hemosol's first hemoglobin-based oxygen carrier. Hemolink is currently in Phase I clinical trials at L.A.B. Pharmacologic Research International Inc. in Montreal, Quebec, Canada.

The invention described in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry